Stockscreener 앱 받기
24.71
3.78%
0.90
시간 외 거래:
25.00
0.29
+1.17%
전일 마감가:
$23.81
열려 있는:
$23.57
하루 거래량:
1.48M
Relative Volume:
1.37
시가총액:
$1.57B
수익:
-
순이익/손실:
$-129.61M
주가수익비율:
-8.2722
EPS:
-2.9871
순현금흐름:
$-116.59M
1주 성능:
+12.52%
1개월 성능:
+15.79%
6개월 성능:
+64.40%
1년 성능:
+264.99%
1일 변동 폭
$23.38
$25.00
1주일 범위
$21.40
$25.00
52주 변동 폭
$6.67
$28.00
Jade Biosciences Inc Stock (JBIO) Company Profile
명칭
Jade Biosciences Inc
전화
(781) 312-3013
주소
221 CRESCENT ST., WALTHAM
Compare JBIO vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JBIO
Jade Biosciences Inc
|
24.71 | 1.48B | 0 | -129.61M | -116.59M | -2.9871 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 개시 | H.C. Wainwright | Buy |
| 2025-10-09 | 개시 | BTIG Research | Buy |
| 2025-07-14 | 개시 | Jefferies | Buy |
| 2025-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-05-07 | 개시 | Wedbush | Outperform |
| 2025-05-05 | 개시 | Stifel | Buy |
| 2025-05-02 | 개시 | TD Cowen | Buy |
| 2024-06-18 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-06-18 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-06-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-06-17 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-06-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-06-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-03-25 | 재개 | Jefferies | Buy |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2022-12-06 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-08-16 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-02-11 | 개시 | BTIG Research | Buy |
| 2021-07-26 | 개시 | Cowen | Outperform |
| 2021-07-26 | 개시 | Evercore ISI | Outperform |
| 2021-07-26 | 개시 | Jefferies | Buy |
| 2021-07-26 | 개시 | Wedbush | Outperform |
모두보기
Jade Biosciences Inc 주식(JBIO)의 최신 뉴스
H.C. Wainwright Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $55 - moomoo.com
HC Wainwright Analysts Increase Earnings Estimates for JBIO - MarketBeat
Jade Biosciences (JBIO) Shares Just Moved, So What Is Going On? - Sahm
Renaissance Technologies LLC Boosts Holdings in Jade Biosciences, Inc. $JBIO - MarketBeat
Jefferies Maintains Jade Biosciences(JBIO.US) With Buy Rating, Raises Target Price to $48 - Moomoo
Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO), Silence Therapeutics (SLN) and Vertex Pharmaceuticals (VRTX) - theglobeandmail.com
A Quick Look at Today's Ratings for Jade Biosciences(JBIO.US), With a Forecast Between $42 to $77 - Moomoo
Jade Biosciences Is Maintained at Buy by BTIG - moomoo.com
Jade Biosciences (NASDAQ:JBIO) Given New $77.00 Price Target at BTIG Research - MarketBeat
Jade Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
JBIO SWOT Analysis: Financial Challenges and Development Opportu - GuruFocus
Jade Biosciences, Inc. Stock 12‑Month Price Target Raised to $46.44, Implies 111% Upside - TradingView
Wedbush raises Jade Biosciences price target on pipeline progress By Investing.com - Investing.com Australia
Wedbush raises Jade Biosciences price target on pipeline progress - Investing.com
Jade Biosciences Releases Q2 2026 Financial Results - AlphaStreet
Jade Biosciences Announces Q2 2026 Financial Results Highlighting Increased R&D and Asset Growth - Kalkine Media
Jade Biosciences Q2 Results: EPS Misses Estimate, Losses Widen - scanx.trade
Jade Biosciences' Q2 Loss Narrows - marketscreener.com
Earnings Flash (JBIO) Jade Biosciences Posts Q2 Loss $0.76 a Share, vs. FactSet Est of $0.63 Loss - marketscreener.com
Jade Biosciences reports Q2 net loss $55.8M, cash $461.2M; advances JADE101 to Phase 2/3 - TradingView
Jade Biosciences (NASDAQ: JBIO) boosts cash to $461M while loss widens - Stock Titan
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Jade Biosciences reports $55.8 million Q2 net loss - Quiver Quantitative
Jade Biosciences Q2 net loss widens as costs rise - TradingView
Jade Biosciences (JBIO) Earnings Date and Reports 2026 $JBIO - MarketBeat
Jade Biosciences Inc expected to post a loss of 64 cents a shareEarnings Preview - TradingView
Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - marketbeat.com
Jade Biosciences (NASDAQ:JBIO) Trading 10% HigherHere's What Happened - marketbeat.com
Jade Biosciences (NASDAQ:JBIO) Shares Down 4.2%Here's What Happened - MarketBeat
Orbimed Advisors LLC Sells 346,152 Shares of Jade Biosciences, Inc. $JBIO - MarketBeat
Jade Biosciences (JBIO) Holds Near $20 Support as Biotech Sentiment WaversSwing Entry Signals - dars.gov.et
Jade Biosciences Ord Shs (JBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
JBIO|Jade Biosciences Ord Shs|Price:21.670|Chg%:+0.320 - TradingKey
Affinity Asset Advisors LLC Decreases Holdings in Jade Biosciences, Inc. $JBIO - MarketBeat
Jade Biosciences, Inc. Revenue Breakdown – NASDAQ:JBIO - TradingView
Paradigm Biocapital Advisors LP Acquires Significant Stake in Ja - GuruFocus
Jade Biosciences Inc. (JBIO) Q1 2026 Earnings: Pre-Revenue Biotech Misses EPS Estimates as Development Costs WeighProfit Announcement - dars.gov.et
Jade Biosciences Company Profile & Introduction - Moomoo
Paradigm funds disclose significant Jade Biosciences (JBIO) ownership in Schedule 13G - Stock Titan
Jade Biosciences Inc. (JBIO) Climbs 1.67% as Stock Tests Near Resistance at $22.37IV Rank - dars.gov.et
Jade Biosciences Inc. (JBIO) Holds Steady Near Key Resistance as Trading Volume Remains CalmHull Moving Average - DonanımHaber
Price to earnings forward of Jade Biosciences, Inc. – NASDAQ:JBIO - TradingView
Price to book forward of Jade Biosciences, Inc. – NASDAQ:JBIO - TradingView
Price to sales forward of Jade Biosciences, Inc. – NASDAQ:JBIO - TradingView
Enterprise value to EBIT forward of Jade Biosciences, Inc. – NASDAQ:JBIO - TradingView
Enterprise value to revenue forward of Jade Biosciences, Inc. – NASDAQ:JBIO - TradingView
Janus Henderson holds 6.27M JBIO shares, reporting 10.6% stake (JBIO) - Stock Titan
JBIOJade Biosciences Inc Options - Finviz
Jade Biosciences (JBIO) Joins Growth Indexes, Is The Stock Still Undervalued? - Sahm
Jade Biosciences to Receive up to $22 Million as Part of Licensing Deal With Paragon Therapeutics - Moomoo
JBIO Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineRevenue Report - dars.gov.et
Jade Biosciences Inc (JBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):